Directed Stem Cell Differentiation for Cell-Based Therapies for Heart, Lung, and Blood Diseases (R21)

The summary for the Directed Stem Cell Differentiation for Cell-Based Therapies for Heart, Lung, and Blood Diseases (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Directed Stem Cell Differentiation for Cell-Based Therapies for Heart, Lung, and Blood Diseases (R21): Purpose. This funding opportunity announcement (FOA) encourages Exploratory/Developmental (R21) grant applications from applicant organizations that propose to define the factors and mechanisms controlling the differentiation of embryonic or adult stem or progenitor cells, either in vitro or in vivo. It is designed to stimulate new scientific advances in stem cell differentiation including technology research that may not be hypothesis driven. The long range goal of this program is the development of methods to direct the differentiation or development of stem cells along specific cell lineages to yield replacement cells for clinical use, whether the replacement cells are formed in vitro for delivery or formed in vivo in the tissue or organ environment. Mechanism of Support. This FOA will utilize the Exploratory/Developmental (R21) grant mechanism, and it runs in parallel with FOAs of identical scientific scope, PA-09-249, that encourages applications under the SBIR [R43/R44] mechanism, and PA-09-250, that encourages applications under the STTR [R41/R42] mechanism. Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism, numbers, quality, duration, and costs of the applications received.

Federal Grant Title:	Directed Stem Cell Differentiation for Cell-Based Therapies for Heart, Lung, and Blood Diseases (R21)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PA-09-248
Type of Funding:	Grant
CFDA Numbers:	93.837
CFDA Descriptions:	Heart and Vascular Diseases Research
Current Application Deadline:	Sep 07, 2012
Original Application Deadline:	Sep 07, 2012
Posted Date:	Aug 12, 2009
Creation Date:	Aug 12, 2009
Archive Date:	Oct 08, 2012
Total Program Funding:
Maximum Federal Grant Award:	$200,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • Chronic Kidney Disease in Children Central Biochemistry Laboratory (U24 Clinical Trial Not...; • Limited Competition for Continuation of the Prospective Study of Chronic Kidney Disease in...; • Limited Competition for Continuation of the Prospective Study of Chronic Kidney Disease in...; • ARDS, Pneumonia, and Sepsis Phenotyping Consortium Clinical Centers (U01 Clinical Trial No...; • The Relationship Between Hypertension and Inflammation; • Community-Responsive Interventions to Reduce Cardiovascular Risk in American Indians and A...; • Weight Loss in Obese Adults with Cardiovascular Risk Factors: Clinical Interventions (U01)
More Grants from the National Institutes of Health: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...; • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...